Journal of Psychopharmacology
May 1, 2026
Otto Simonsson, Taylor Lyons, Joseph Marks et al.
Previous research suggests that psychedelics may, under certain conditions, decrease authoritarian attitudes, but larger and more rigorously designed studies are needed to confirm these findings. We aimed to examine the effects of psychedelic use on authoritarian attitudes. Using data from three separate studies with different designs and populations, we investigated the relationship between...
Journal of Psychopharmacology
May 1, 2026
Otto Simonsson, Sunjuri Sun, Laura W. Wesseldijk et al.
While psychedelics have shown initial promise in the treatment of migraine, experimental studies have relied on small and homogenous samples, which limit the reliability and generalizability of findings. These limitations underscore the complementary value of other research designs that leverage larger and more representative samples. This cross-sectional study included three cohorts of twins...
Psychopharmacology
April 29, 2026
Anne-Fiona Griesfeller, Lotte Kooman, Lilian Kloft-Heller et al.
RATIONALE: Reports of resurfaced repressed memories during psychedelic experiences have circulated for decades and still emerge today. However, the veracity of repressed memories remains debated, and the mechanisms through which psychedelics might recover alleged repressed memories are unclear. OBJECTIVES: This scoping review aimed to provide an overview of the literature on repressed memory in...
Journal of Medical Internet Research
April 27, 2026
Karilynn M Rockhill, Elizabeth A Bemis, Nicole Schow et al.
2 citations
Mainstays of pharmacoepidemiology are large, representative, behavioral surveys, which focus on many drugs with few detailed behaviors. Smaller, targeted studies measure drug-specific patterns but without explicit generalizability assumptions; the evidence generated is narrow. In this cross-sectional survey study, we outline an estimation framework based on data fusion and combine two surveys:...
Journal of Mental Health Disorders
April 18, 2026
Vipul Janardan, Amit Khanna, Om Prakash et al.
Psychedelics a class of psychoactive compounds such as psilocybin, lysergic acid diethylamide (LSD), and dimethyltryptamine (DMT) are undergoing a scientific renaissance. Studies since 2020 have shown their therapeutic promise in mental health treatment. This Commentary synthesizes historical usage, current neuroscientific and clinical evidence, and explores ethical and regulatory frontiers for...
Psychedelic Medicine
April 9, 2026
Alex C. Kwan
Psychedelics rose to prominence in the 1960s, around the same time when neurobiologists identified the midbrain raphe as the brain’s primary source of serotonin. It is therefore no surprise that early studies on classical psychedelics like d -lysergic acid diethylamide (LSD) focused on their effects within this brainstem nucleus. This review traces the arc of discovery: from the initial report...
Pharmacology Research & Perspectives
April 1, 2026
Jordana Kazdan, Karim S Ladha, Muhammad Ishrat Husain
Major Depressive Disorder (MDD) and chronic pain are independently debilitating conditions that frequently co-occur. This comorbidity poses a significant clinical challenge, resulting in greater symptom severity, higher disability, and worse prognosis than either condition alone. Current therapies often address each disorder in isolation, leaving individuals with comorbid MDD and chronic pain...
Journal of Psychedelic Studies
March 26, 2026
Aly Shah Aziz
Abstract Adolescent refractory mental health disorders are rising globally, contributing to long-term morbidity and substantial societal burden. Conventional psychotropic medications and psychotherapeutic approaches sometimes fail to provide adequate relief, necessitating an interest in novel investigational interventions. Classic psychedelic compounds—Psilocybin, Lysergic Acid Diethylamide...
Neurology Bulletin
March 23, 2026
Azat R. Asadullin, Elvina A. Akhmetova, Ilia S. Efremov et al.
BACKGROUND: Substance use disorders remain a global public health problem. In recent decades, the drug market has undergone substantial changes, with traditional drugs increasingly replaced by new psychoactive substances characterized by high toxicity and strong addictive potential. Their distribution via the Internet and social media impedes control and increases risks to public health. AIM:...
Child and Adolescent Psychiatry and Mental Health
March 13, 2026
Marc-Antoine Crocq, Philippe Auby
Aims The recent regulatory approval of esketamine in adults heralded the renaissance of research into psychedelic compounds. However, the relevance of this resurgence for children and adolescents remains unclear. This review examines the rationale for investigating psychedelics in pediatric psychopharmacology. Methods We reviewed recent literature, regulatory documents, and clinical trial...